Source Capital (NYSE:SOR) & Dominari (NASDAQ:DOMH) Critical Review

Dominari (NASDAQ:DOMH) and Source Capital (NYSE:SOR) are both small-cap finance companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for Dominari and Source Capital, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1	0	0	0	1.00
Source Capital	0	0	0	0	0.00

Valuation & Earnings

This table compares Dominari and Source Capital”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10 million	0.41	-$22.43 million	($5.39)	-0.39
Source Capital	N/A	N/A	N/A	N/A	N/A

Source Capital has lower revenue, but higher earnings than Dominari.

Profitability

This table compares Dominari and Source Capital’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-51.61%	-235.37%	-163.66%
Source Capital	N/A	N/A	N/A

Volatility and Risk

Dominari has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Source Capital has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Institutional and Insider Ownership

42.5% of Dominari shares are owned by institutional investors. Comparatively, 13.2% of Source Capital shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 77.0% of Source Capital shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Source Capital

Source Capital, Inc. is a close-ended balanced fund launched and managed by First Pacific Advisors, LLC. The fund invests in the public equity markets of the United States. It seeks to invest in the stocks of companies operating across diversified sectors. The fund primarily invests in value stocks of small to mid cap companies. It employs fundamental analysis with a bottom-up stock selection approach, focusing on such factors as high liquidity, relatively unleveraged balance sheets, and long-term ability to earn above-average returns on capital to create its portfolio. The fund benchmarks the performance of its portfolio against the Russell 2500 Index, the S&P 500 Index, and the Nasdaq Composite Index. Source Capital, Inc. was formed in June 1, 1968 and is domiciled in the United States.